Service de Rhumatologie, Paris Descartes Université, Hôpital Cochin, AP-HP, 27, rue du Faubourg Saint-Jacques, 75014 Paris, France.
Service de Virologie, Paris Descartes Université, Hôpital Cochin, AP-HP, 27, rue du Faubourg Saint-Jacques, 75014 Paris, France.
Joint Bone Spine. 2022 May;89(3):105312. doi: 10.1016/j.jbspin.2021.105312. Epub 2021 Dec 6.
To estimate the seroprevalence of SARS-CoV-2 infection in patients with rheumatic diseases and to specify the proportion of asymptomatic and symptomatic forms of COVID-19.
We screened for SARS-CoV-2 infection among spondyloarthritis (SpA, n=143) or rheumatoid arthritis (RA, n=140) patients in our outpatient clinic at Cochin Hospital in Paris between June and August 2020. We performed a qualitative SARS-CoV-2 serological test which detects IgG directed against the N nucleocapsid protein (anti-N) and, for some patients, against the Spike protein (anti-S). Descriptive analyses were managed.
During June-August 2020, the SARS-CoV-2 seroprevalence rate in our population was 2.83% (8/283 patients) without significant difference between RA and SpA patients (2.14% and 3.5%, respectively). We report 11 out of 283 patients (3.8%) with a diagnosis of SARS-CoV-2 infection. Among these 11 patients, 1 patient was asymptomatic (9%) with a confirmed diagnosis of COVID-19 by anti-S serology. Of the 283 patients, 85% were under bDMARDs, mainly on rituximab (RTX) (n=44) and infliximab (IFX) (n=136).
The seroprevalence of SARS-CoV-2 in patients with rheumatic diseases, mainly under bDMARDs treatments, was 2.83%. Among infected patients, 9% were asymptomatic. Detecting SARS-CoV-2 infections could be based on the strategy using patients' interview and anti-N serology.
评估风湿性疾病患者中 SARS-CoV-2 感染的血清流行率，并明确 COVID-19 的无症状和有症状形式的比例。
我们在 2020 年 6 月至 8 月期间，在巴黎 Cochin 医院的门诊中筛查了 143 例强直性脊柱炎（SpA）或 140 例类风湿关节炎（RA）患者的 SARS-CoV-2 感染情况。我们进行了定性 SARS-CoV-2 血清学检测，检测 IgG 针对 N 核衣壳蛋白（抗-N），并对一些患者进行了 Spike 蛋白（抗-S）检测。进行了描述性分析。
在 2020 年 6 月至 8 月期间，我们人群中的 SARS-CoV-2 血清流行率为 2.83%（283 例患者中有 8 例），RA 和 SpA 患者之间无显著差异（分别为 2.14%和 3.5%）。我们报告了 283 例患者中有 11 例（3.8%）诊断为 SARS-CoV-2 感染。在这 11 例患者中，有 1 例患者无症状（9%），COVID-19 通过抗-S 血清学确诊。在 283 例患者中，85%正在接受 bDMARDs 治疗，主要为利妥昔单抗（RTX）（n=44）和英夫利昔单抗（IFX）（n=136）。
风湿性疾病患者，主要在 bDMARDs 治疗下，SARS-CoV-2 的血清流行率为 2.83%。在感染患者中，9%为无症状。可以根据患者访谈和抗-N 血清学检测来检测 SARS-CoV-2 感染。
